Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Eiger BioPharmaceuticals Inc.
DescriptionGlucagon-like peptide-1 (GLP-1) receptor antagonist
Molecular Target Glucagon-like peptide-1 (GLP-1)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHypoglycemia
Indication DetailsTreat post-bariatric hypoglycemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today